A carregar...
Mirabegron: a review of recent data and its prospects in the management of overactive bladder
Mirabegron is a novel, once-daily, orally active, first-in-class, potent β(3)-adrenoceptor agonist recently approved by Food and Drug Administration for overactive bladder therapy. Phase II studies and four large-scale phase III multinational randomized, controlled trials have supported the efficacy...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3491758/ https://ncbi.nlm.nih.gov/pubmed/23205058 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287212457114 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|